Nassau County
GOP Grifter George Santos Declares “I Will Not Resign”
HipHopWired Featured Video Source: Win McNamee / Getty Embattled congressman George Santos has broken his silence to insist he will not resign over growing calls to step down over his growing history of lying about his past. On Wednesday afternoon (Jan. 11), as the freshman Republican congressman was leaving his office, he was asked about the calls to resign from local officials of his party by ABC reporter Rachel Scott. “Will you step down?”, she asked. Santos swiftly answered, “I will not.” As he stepped onto the elevator, he refused to answer further questions from other reporters. Related Stories Santos would later take a more defiant tone on social media. “I was elected to serve the people of #NY03, not the party & politicians, I remain committed to doing that and regret to hear t...
Gold rises on renewed US stimulus hope, dollar falls
Spot gold rose 0.3 percent to $1,910.56 an ounce at 3:37pm, New York time, after falling as much as 0.5 percent. Gold rose on renewed optimism for a preelection aid package in the U.S., while the dollar fell to a one-week low. House Speaker Nancy Pelosi said a bill for a compromise stimulus package is being written as she awaits a key phone call with Treasury Secretary Steven Mnuchin. Senate Majority Leader Mitch McConnell said his chamber would take up a comprehensive coronavirus package if an accord is struck. The Bloomberg Dollar Spot Index headed for the third straight decline. Pelosi said in a Bloomberg Television interview that while there are areas where more work is required to get a compromise, she was pleased with the Trump administration’s latest position on coronavirus testing ...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
